TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price target among brokerages that have covered the stock in the last year is $49.00.

A number of equities research analysts recently commented on the stock. B. Riley increased their price objective on shares of TG Therapeutics from $53.00 to $55.00 and gave the company a "buy" rating in a research note on Wednesday, September 17th. Weiss Ratings restated a "hold (c-)" rating on shares of TG Therapeutics in a research report on Wednesday. The Goldman Sachs Group upgraded TG Therapeutics to a "hold" rating and set a $37.00 target price on the stock in a report on Thursday, July 10th. Finally, HC Wainwright began coverage on TG Therapeutics in a research report on Monday, October 6th. They set a "buy" rating and a $60.00 price target for the company.

Insiders Place Their Bets

In other TG Therapeutics news, Director Sagar Lonial sold 20,852 shares of the company's stock in a transaction dated Thursday, September 11th. The shares were sold at an average price of $32.24, for a total value of $672,268.48. Following the transaction, the director directly owned 94,061 shares in the company, valued at approximately $3,032,526.64. This represents a 18.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.64% of the company's stock.

Institutional Trading of TG Therapeutics

Hedge funds have recently bought and sold shares of the company. Ameritas Advisory Services LLC purchased a new stake in TG Therapeutics in the 2nd quarter worth approximately $25,000. Johnson Financial Group Inc. acquired a new stake in shares of TG Therapeutics during the second quarter worth $25,000. NBC Securities Inc. grew its position in shares of TG Therapeutics by 82,300.0% in the first quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock valued at $32,000 after purchasing an additional 823 shares during the period. Golden State Wealth Management LLC increased its stake in TG Therapeutics by 100.0% in the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 433 shares during the last quarter. Finally, SVB Wealth LLC purchased a new position in TG Therapeutics during the first quarter worth about $37,000. Institutional investors and hedge funds own 58.58% of the company's stock.

TG Therapeutics Trading Down 3.5%

Shares of TGTX opened at $33.76 on Friday. The firm's 50-day moving average is $31.51 and its two-hundred day moving average is $35.21. The firm has a market capitalization of $5.36 billion, a P/E ratio of 91.24 and a beta of 1.97. The company has a current ratio of 3.86, a quick ratio of 2.96 and a debt-to-equity ratio of 0.89. TG Therapeutics has a twelve month low of $21.65 and a twelve month high of $46.48.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.15). The firm had revenue of $141.15 million during the quarter, compared to analysts' expectations of $147.76 million. TG Therapeutics had a net margin of 13.31% and a return on equity of 26.05%. The business's revenue for the quarter was up 92.1% on a year-over-year basis. During the same period in the previous year, the business earned $0.04 earnings per share. TG Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts predict that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.